论文部分内容阅读
目的 :探讨吉西他滨+顺铂+地塞米松化疗方案在复发性非霍奇金淋巴瘤的临床疗效。方法 :36例非霍奇金淋巴瘤复发的患者,均应用吉西他滨+顺铂+地塞米松化疗方案进行治疗,4周为1个周期。6个周期后对36例患者进行12个月的随访,观察患者的治疗效果及不良反应。结果 :36例患者均完成6个周期的化疗,且完成随访。其中CR7例(19.44%),PR12例(33.33%),SD6例(16.66%),PD11例(30.55%),RR52.77%。不良反应发生率:粒细胞减少为35.33%,血小板减少为23.36%,胃肠道反应为42.57%,肝肾功能损害为9.73%,贫血为12.62%。36例患者在治疗过程中发生的不良反应均较轻,骨髓抑制大部分为Ⅰ度或者Ⅱ度,只有2例Ⅲ度骨髓抑制,经升高白细胞处理后回复正常,没有出现Ⅳ度骨髓抑制;胃肠道反应亦较轻,均为Ⅰ度或者Ⅱ度胃肠道反应,经对症处理后恢复;肝肾功能损害发生少,且均为轻度,经护肝、护肾处理后恢复;贫血发生率亦低,均为轻-中度贫血,其中最严重的一例HB75g/L,化疗结束后自行恢复。结论 :吉西他滨+顺铂+地塞米松化疗方案在复发性非霍奇金淋巴瘤的化疗效果好,毒副反应轻,大部分接受治疗的患者获益。
Objective: To investigate the clinical efficacy of gemcitabine + cisplatin + dexamethasone chemotherapy in recurrent non-Hodgkin’s lymphoma. Methods: Thirty-six patients with recurrent non-Hodgkin’s lymphoma were treated with gemcitabine + cisplatin plus dexamethasone chemotherapy for 4 weeks for one cycle. After 6 cycles of 36 patients were followed up for 12 months to observe the treatment of patients and adverse reactions. Results: All 36 patients completed 6 cycles of chemotherapy and were followed up. Among them, CR7 (19.44%), PR12 (33.33%), SD6 (16.66%), PD11 (30.55%), RR52.77%. The incidence of adverse reactions: neutropenia was 35.33%, thrombocytopenia was 23.36%, gastrointestinal reactions were 42.57%, liver and kidney dysfunction was 9.73%, anemia was 12.62%. Thirty-six patients had mild adverse reactions during the course of treatment. The majority of myelosuppression was degree Ⅰ or Ⅱ, and only 2 patients with grade Ⅲ myelosuppression returned to normal after treatment with leukocytes. There was no grade Ⅳ myelosuppression. Gastrointestinal reactions are also lighter, are Ⅰ or Ⅱ degree gastrointestinal reactions, after symptomatic treatment and recovery; liver and kidney dysfunction occurred less, and are mild, the protection of the liver, kidney treatment and recovery; anemia The incidence is also low, are mild to moderate anemia, one of the most serious case of HB75g / L, self-recovery after chemotherapy. Conclusions: Gemcitabine + cisplatin + dexamethasone chemotherapy is effective in recurrent non-Hodgkin’s lymphoma with mild side effects, and most patients receiving treatment benefit.